Satellite symposia are non-commercial, grant- funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2025. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.
Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.
Satellite program information will be available in late January.
For more information, please contact us.
- Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 330
Managed Care Considerations for Managing Myelofibrosis With JAK Inhibitors
Provider: Medscape LLC
Supported by: Supported by an independent educational grant from GSK
Continuing education: For Pharmacists
Contact hours: 1.5
Medscape designates this continuing education activity for 1.50 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-25-007-L01-P).
Program Description
This symposium will feature a panel of 3 expert faculty discussing best practices to optimize the use of JAK inhibitors in managed care pharmacy settings as part of the treatment plan for patients with myelofibrosis.
Learning ObjectivesUpon completion of this activity, participants will:
- Have increased knowledge regarding the - Managed care pharmacy considerations that impact use of JAK inhibitors in management of MF
- Characteristics of JAK inhibitors that drive decision making
- Have greater competence related to - Implementing pharmacy benefit design to improve access to JAK inhibitors in management of MF
- Demonstrate greater confidence in their ability to - Optimize use of JAK inhibitors as part the MF treatment plan in managed care settings
Program Manager
Nora Pettit
Medscape LLC
npettit@medscapelive.com
- Wednesday, April 2, 2025 | 11:30 am - 1:30 pm
-
Location: 330
Precision Meets Value: Elevating Outcomes in Relapsed/Refractory Multiple Myeloma With CAR T-Cell and Bispecific Antibody Therapies
Provider: PRIME Education, LLC
Supported by: Janssen Scientific Affairs, LLC, Legend Biotech, BMS (Pending)
Continuing education: ACPE credit for managed care pharmacists, medical and pharmacy directors, and medication therapy management (MTM) nursing directors working in managed care organizations, pharmacy benefit organizations, and specialty pharmacies
Contact hours: 1.5Program Description
The 1.5-hour live symposium and live stream will be led by a panel of one nationally renowned expert in MM, a managed care pharmacist and moderated by a clinical pharmacist to facilitate panel discussions, conduct polling, and triage questions from the audience.
The symposium’s agenda will feature real-world insights from a new managed care pharmacist survey and expert discussion on the latest evidence for bispecific antibody and CAR T-cell therapies in R/R MM, with a focus on overcoming managed care challenges and improving patient outcomes. To maximize audience engagement, the presentation will integrate real-time polling and case-based discussions supplemented by pre-submitted attendee questions and a dedicated Q&A session.
Agenda
I. Shifting the Paradigm: The Role of CAR T-Cell and Bispecific Antibody Therapies in R/R MM
a. Key updates from clinical trials and their implications for earlier treatment with CAR T-cell therapy in R/R MM
b. Optimizing patient outcomes in R/R MM: Case-based discussions
II. Real-World Insights: Survey of Managed Care Pharmacists on the Challenges and Opportunities With CAR T-Cell Therapies and Bispecific T-Cell Engagers
III. Financial Toxicity and Healthcare Resource Management: Strategies for Managed Care Pharmacists
a. Cost considerations for bispecific and CAR T-cell therapies
b. Innovative reimbursement models, such as outcome-based pricing
c. Best practices for financial navigation, outpatient management of CRS, and remote patient monitoring
d. The role of managed care pharmacists in advocating for expanded networks of certified CAR T-cell centers
IV. Q&A Session
Learning Objectives
- Analyze the latest efficacy and safety data on chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies to inform formulary decisions for relapsed/refractory multiple myeloma (R/R MM)
- Apply evidence-based strategies to optimize patient selection criteria for CAR T-cell therapies and bispecific antibodies in R/R MM management, based on patient- and disease-specific factors
- Assess the impact of early identification and management of adverse events (AEs) in patients receiving CAR T-cell therapies and bispecific antibodies to enhance safety and reduce costs
- Evaluate the cost-effectiveness and financial implications of utilizing CAR T-cell therapies and bispecific antibodies in managed care settings for R/R MM treatment
- Employ strategies to mitigate financial toxicity for R/R MM patients undergoing treatment with CAR T-cell therapies and bispecific antibodies
Program Manager
Stephanie Yang
PRIME Education
s.yang@primeinc.org